Evidence map›Paper›PMID 40053260›Full record

ReviewMolecular biology reports2025

Advancement insights in cancer vaccines: mechanisms, types, and clinical applications.

Gellan Alaa Mohamed Kamel, Rasha A Attia, Hifaa G Al-Noman, Lamiaa A Salama

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gellan Alaa Mohamed KamelDepartment of Pharmacology and Toxicology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt. gelan.alaa@azhar.edu.eg.ORCID http://orcid.org/0000-0001-6980-4726
Rasha A AttiaDepartment of Pharmacognosy, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt.
Hifaa G Al-NomanNogoud Medical Centre, Ministry of Health, Almadinah Almowarah, Saudi Arabia.
Lamiaa A SalamaMicrobiology and Immunology Department, Faculty of Pharmacy, Horus University, New Damietta, 34518, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy can treat cancer by boosting the immune system to mark and destroy cancer cells. Cancer vaccine is a promising therapeutic strategy in immunotherapy. Cancer vaccines are divided into four groups according to different preparation techniques: cell-based vaccine, virus-based vaccine, peptide-based vaccine, and nucleic acid-based vaccine. Cancer vaccines can be given with traditional treatments or another immunotherapy to give better results and overcome tumor resistance. The cancer vaccine is a promising immunotherapy that could stimulate the immune response to kill cancer cells and create immune surveillance. However, much work is still needed to identify neoantigens, optimize the vaccination platform, and develop combination therapy to improve the efficacy of immunotherapy. This review highlights the mechanism of action of cancer vaccines, the main four groups of cancer vaccines regarding their development, research progress, and clinical applications, and how to assess immune response following cancer vaccination.

Indexed as

Cancer VaccinesImmunotherapyNeoplasmsAnimalsAntigens, NeoplasmHumansVaccines, SubunitAntigens, NeoplasmCancer VaccinesVaccines, SubunitCancer immune cycleCancer vaccineClinical applicationTumor antigens

Identifiers

PMID40053260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.